Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 23582304)


A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Douglas JL, Bai Y, Gustin JK, Moses AV.

Virology. 2013 Jul 5;441(2):182-96. doi: 10.1016/j.virol.2013.03.015. Epub 2013 Apr 10.


The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.

Kluge SF, Sauter D, Vogl M, Peeters M, Li Y, Bibollet-Ruche F, Hahn BH, Kirchhoff F.

Retrovirology. 2013 Mar 20;10:32. doi: 10.1186/1742-4690-10-32.


Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.

Yoshida T, Koyanagi Y, Strebel K.

J Virol. 2013 Dec;87(24):13825-36. doi: 10.1128/JVI.02567-13. Epub 2013 Oct 9.


Human immunodeficiency virus-1 BF intersubtype recombinant viral protein U second α helix plays an important role in viral release and BST-2 degradation.

De Candia C, Espada C, Duette G, Salomón H, Carobene M.

J Gen Virol. 2013 Apr;94(Pt 4):758-66. doi: 10.1099/vir.0.047746-0. Epub 2012 Dec 5.


Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.

Lv M, Wang J, Wang X, Zuo T, Zhu Y, Kong W, Yu X.

PLoS One. 2011;6(6):e20890. doi: 10.1371/journal.pone.0020890. Epub 2011 Jun 2.


Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Vigan R, Neil SJ.

J Virol. 2010 Dec;84(24):12958-70. doi: 10.1128/JVI.01699-10. Epub 2010 Oct 6.


Lack of adaptation to human tetherin in HIV-1 group O and P.

Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM.

Retrovirology. 2011 Sep 28;8:78. doi: 10.1186/1742-4690-8-78.


Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.

Gustin JK, Douglas JL, Bai Y, Moses AV.

J Biol Chem. 2012 Apr 27;287(18):14837-50. doi: 10.1074/jbc.M112.349928. Epub 2012 Mar 1.


Identification of novel key amino acids at the interface of the transmembrane domains of human BST-2 and HIV-1 Vpu.

Pang X, Hu S, Li J, Xu F, Mei S, Zhou J, Cen S, Jin Q, Guo F.

Retrovirology. 2013 Aug 6;10:84. doi: 10.1186/1742-4690-10-84.


Vpu binds directly to tetherin and displaces it from nascent virions.

McNatt MW, Zang T, Bieniasz PD.

PLoS Pathog. 2013;9(4):e1003299. doi: 10.1371/journal.ppat.1003299. Epub 2013 Apr 25.


Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.

Jafari M, Guatelli J, Lewinski MK.

J Virol. 2014 May;88(9):5062-78. doi: 10.1128/JVI.03472-13. Epub 2014 Feb 26.


HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.

Fritz JV, Tibroni N, Keppler OT, Fackler OT.

Virology. 2012 Mar 1;424(1):33-44. doi: 10.1016/j.virol.2011.12.008. Epub 2012 Jan 4.


Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.

Lim ES, Malik HS, Emerman M.

J Virol. 2010 Jul;84(14):7124-34. doi: 10.1128/JVI.00468-10. Epub 2010 May 5.


Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.

Lau D, Kwan W, Guatelli J.

J Virol. 2011 Oct;85(19):9834-46. doi: 10.1128/JVI.02633-10. Epub 2011 Aug 3.


Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317.

Bolduan S, Votteler J, Lodermeyer V, Greiner T, Koppensteiner H, Schindler M, Thiel G, Schubert U.

Virology. 2011 Jul 20;416(1-2):75-85. doi: 10.1016/j.virol.2011.04.009. Epub 2011 May 23.


β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.

Tervo HM, Homann S, Ambiel I, Fritz JV, Fackler OT, Keppler OT.

Retrovirology. 2011 Feb 10;8:9. doi: 10.1186/1742-4690-8-9.


Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.

Dubé M, Roy BB, Guiot-Guillain P, Binette J, Mercier J, Chiasson A, Cohen EA.

PLoS Pathog. 2010 Apr 8;6(4):e1000856. doi: 10.1371/journal.ppat.1000856.


Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT.

PLoS Pathog. 2009 May;5(5):e1000429. doi: 10.1371/journal.ppat.1000429. Epub 2009 May 15.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk